REIMAGINE
Summary
This study is being done to better understand how well the medication mepolizumab (NUCALA) is working in routine medical practice to treat a sub-population of adult patients with severe asthma who have what is termed an eosinophilic phenotype (SA-EP). Mepolizumab is approved (marketed drug) in Canada.
Study participants will be asked to complete questionnaires and lung function testing in addition to their standard of care visit.
Participation in the study will last 2 years.
Eligibility
Eligible ages: 18 to 80
Inclusion criteria:
You might be eligible if:
1) 18 years or over
2) You have severe asthma with an eosinophilic phenotype
3) You have been prescribed NUCALA
Exclusion criteria:
You may not be eligible if:
1) Under the age of 18
2) You do not have severe asthma with an eosinophilic phenotype
3) You are pregnant
4) You are a current smoker
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
If you are interested in learning more about this study, please contact the study coordinator, Madison, at 403-210-7827.
Principal investigator:
Richard Leigh
Clinical trial:
Yes
REB-ID:
REB24-0130
External links